EP0528842A4 - Methods of tissue implantation - Google Patents

Methods of tissue implantation

Info

Publication number
EP0528842A4
EP0528842A4 EP19910908414 EP91908414A EP0528842A4 EP 0528842 A4 EP0528842 A4 EP 0528842A4 EP 19910908414 EP19910908414 EP 19910908414 EP 91908414 A EP91908414 A EP 91908414A EP 0528842 A4 EP0528842 A4 EP 0528842A4
Authority
EP
European Patent Office
Prior art keywords
tissue
cam
mammalian
implantation
egg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910908414
Other languages
English (en)
Other versions
EP0528842A1 (fr
Inventor
David L. Berliner
Larry J. Stensaas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pherin Corp
Original Assignee
Pherin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pherin Corp filed Critical Pherin Corp
Publication of EP0528842A1 publication Critical patent/EP0528842A1/fr
Publication of EP0528842A4 publication Critical patent/EP0528842A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0627—Hair cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • C12N2533/92—Amnion; Decellularised dermis or mucosa

Definitions

  • This invention relates generally to methods of implanting and reimplanting mammalian tissue in mammals. More specifically, the invention relates to: procedures which increase implantation efficiency; methods of treatment which involve implantation; and tissue compositions useful for implantation.
  • CAM chorioallantoic membrane
  • the CAM was commonly used to study the growth of small tumor transplants (Karnofsky et al, Ann NY Acad Sci (1952) 5_5:313. More recently, it has been used in studies of membrane transport, gas exchange, and angiogenic activity. The CAM has also been used in developmental studies as a substrate for the growth of many types of embryonic avian tissues and organ primordia (Rawles, Ann NY Acad Sci (1952) 55:302) .
  • Implantation is an important step in the early development of mammalian embryos. Techniques of in vitro fertilization are being more widely applied, employing both immediate and cryogenically delayed implantation (Camus, M. et al, Fert and Steril (1989) 51:460), but again implantation efficiency has proven to be a limitation (Liu, H.C. et al, Fert and Steril (1988) 49:649). iemer et al (Fert and Steril (1989) 52:503) has reported that implantation efficiency increases if human zygotes are co-cultured on a monolayer of fetal bovine uterine fibroblasts.
  • One embodiment of the invention is a method of treating a mammal in need of tissue implantation which comprises: providing a developing amniote egg that has a chorioallantoic membrane (CAM) ; implanting mammalian cells or tissue on or in the CAM so as to produce a conditioned mammalian tissue comprising a population of cells; removing the conditioned tissue from the CAM by a means for excision; and, implanting the conditioned tissue in the mammal.
  • CAM chorioallantoic membrane
  • the invention is used to treat both genetic and metabolic deficiencies of gene expression. In still another embodiment, the invention is used to treat alopecia. In other embodiments, the invention is used to treat Parkinsonism. In yet another embodiment, the invention is sed to facilitate the implantation of mammalian preimplantation embryos into the uterine epithelium of recipient mothers. In another embodiment, the invention provides a method of in vitro fertilization of mammalian oocytes. In a final embodiment, the invention is a composition of tissues useful for mammalian implantations which composition comprises mammalian tissue and growth factors derived from an avian CAM.
  • An “allogeneic” implant comprises cells or tissue which have a different genetic constitution than the host tissue; this because they are obtained from a subject other than the recipient.
  • An “autogenic” implant comprises cells or tissue originating within the body of the recipient (with the same genetic constitution) .
  • a “homotypic” implant comprises cells or tissue of the same genetic constitution and the same type and function.
  • “Amplified” tissue is substantially increased in mass as a result of mitotic growth.
  • An "amniote egg” has a shell and retains its own water supply when external to the parent. It contains a yolk and abundant albumin. The embryo develops within the egg, but external to the parent. Examples include avian and reptile eggs.
  • Conditioned tissue has been grown on the CAM and, as a result, is amplified and substantially vascularized.
  • a "developing" egg is a fertilized amniote egg which has begun ontogenesis in response to the appropriate conditions of incubation.
  • a "fertilization unit” is comprised of a mammalian embryo, usually at the blastocyst stage of development, and mammalian uterine epithelial tissue into which the embryo has been implanted. Prior to the implantation of the embryo, the uterine epithelial tissue has been implanted beneath the choroid epithelium of the CAM of a developing amniote egg such as a chicken or ostrich egg. The fertilization unit is subsequently reimplanted in vivo into the uterine epithelium of the mammalian mother.
  • Implantation is the moving of tissue from one site to another and embedding the moved tissue such that it remains viable.
  • Tissue can be implanted at a new site in the original subject or in a heterologous recipient.
  • the implanted tissue can be placed within tissue of similar function or of different function.
  • a subject which is "in need of” a medical or surgical procedure is one who has an injury, disease, deficiency or medical condition that would likely be ameliorated by the procedure; or alternatively, a subject whose normal physiologic process (e.g. embryo implantation during pregnancy) would be facilitated by the procedure or function.
  • a "neurological impairment” is an injury, disease or degeneration of nerve cells or nervous tissue resulting in a loss of nerve function.
  • a DNA "structural sequence” encodes a polypeptide.
  • Transplantation is a form of implantation in which the tissue being moved is united with the same tissue-type in another place. If the transplant is from one part of the body to another part it is an “autotransplantation” which is equivalent to a homotypic implant.
  • Vascularized tissue has developed new blbod vessels which are patent to the circulation of the host.
  • tissue implantation and transplantation Several injuries, diseases and deficiencies are treatable by tissue implantation and transplantation.
  • tissue implantation Several normal physiologic processes such as mammalian pregnancy involve tissue implantation. The effectiveness of these treatments and the success of these processes is directly related to the efficiency of implantation of the newly introduced tissue as measured by the sustained growth and differentiated function of the implanted tissue.
  • the methods of conditioning tissue, and its subsequent use in treatment involve providing an amniote egg with an embryo that has developed a chorioallantoic membrane (CAM) , and implanting mammalian cells or tissue, which are intended to be subsequently implanted in the recipient mammal, onto or into the CAM.
  • CAM chorioallantoic membrane
  • the tissue grows and is amplified on or in the CAM as the embryo continues to develop, because patency is established between the circulatory system of the egg and the vasculature of the implant; and because the embryonic environment is rich in nutrient and growth factors.
  • the implant tissue becomes hyper-vascularized in response to embryo angiogenic factors.
  • the conditioned mammalian tissue is subsequently excised, along with adherent portions of the CAM, and implanted in a location in the mammalian host which is best suited to the particular treatment regime.
  • the efficiency of implantation is greatly improved, relative to direct tissue implantation, due to the hypervascularization of the implanted tissue, and the tendency of the adherent embryonic vessels to rapidly form functional connections with capillaries of the host tissue.
  • growth factors, provided by the embryonic tissue may also accompany the implant and promote its integration into the transplantation site.
  • an egg of the class Reptilia or Aves is used.
  • eggs of the genus Gallus (chicken) are used. Fertile chicken eggs which have been examined and certified free of pathogens are readily available from commercial sources. Methods of artificial incubation are known to those skilled in the art.
  • eggs of the genus Struthio (ostrich) are used. While eggs certified pathogen-free are not presently available commercially, ostriches and eggs are commercially available (Big Sky Ostrich Collins, Plentywood, Montana) and the eggs can be monitored to meet the same standards that are presently used for chick eggs. These methods are generally known to those skilled in the art.
  • the age of the chick embryo determines the amount of mammalian tissue to be implanted.
  • a larger amount of implant tissue requires a more vascularized CAM surface and an increased pumping capacity of the chick heart (an older chick embryo) , which in turn provides a more adequate flow of blood.
  • the air space at one end of the egg is identified by holding the egg above a small, low intensity light source (candling) and a small (one millimeter) hole is made to allow air to enter the air space.
  • the embryo and the extra-embryonic membranes are then identified, and an "x" is placed with a lead pencil over the mid-portion of the air space to mark its location.
  • a 1 centimeter square window is outlined in the shell centered around the "x" by inscribing lines by means of a small triangular file. The grooves so created are progressively deepened to the egg membrane below.
  • the surface of the egg is cleaned by wiping the area around the "x" with a cotton swab containing 80% ethanol solution for a few seconds and the surface is allowed to dry.
  • the window is then removed by inserting the tip of a pair of sterile watchmaker's forceps under one corner of the square and lifting to expose the underlying egg membrane.
  • the egg membrane is carefully penetrated with the tip of the sterile watchmaker's forceps to permit air to enter so that the CAM will detach and
  • This membrane is then incised with a sterile scalpel and carefully removed by tearing it away from the perimeter of the window to expose the CAM.
  • the surface of the CAM is inspected at low magnification under a dissecting microscope in order to identify the principal vessels that are then traced to a point of convergence where they form the allantoic vascular supply to the embryo.
  • a provisional site is identified near the convergence of the vessels on the CAM surface for the implantation of mammalian tissue, and the choroid epithelium gently abraded with the tip of a sharp glass needle to provide one or more implantation sites.
  • the window is temporarily closed by placing a small piece of Scotch brand tape over the aperture.
  • An implant of living tissue is secured under sterile conditions from a deeply anesthetized mammal. Small pieces of live tissue are secured (not exceeding 1 millimeter x 3 millimeters x 1 millimeter) by rapid dissection. The tissue is either immediately placed onto the previously identified CAM implantation site or quickly transferred into a cold (4 degrees Celsius) sterile culture solution situated in a Petri dish.
  • the cold solution favors survival of cells in the tissue by reducing its metabolic requirements and by permitting diffusion of leukotrienes and proteins induced by injury which would otherwise create a local inflammatory reaction on the CAM.
  • the tissue then undergoes final trimming to remove surrounding connective tissue and reduction to the desired size. This step is critical to insure the rapid fusion of the choroid vessels with microvasculature elements exposed at the surface of the implant. This is discussed further infra.
  • the egg is then opened by removal of the tape cover, and the previously identified implantation site is positioned under the egg center of the window by gently rotating the egg.
  • the small pieces of tissue to be implanted are removed from the Petri dish by means of sterile forceps placed gently under each piece, and lifted out of the culture medium. Excess culture medium is rapidly blotted by resting the forceps on sterile absorbent paper, and then delivered to the CAM with a minimal residual quantity of fluid remaining on the surface.
  • tissue is gently placed on the surface of the CAM implantation site and carefully moved over the previously abraded surface to secure good contact without inducing additional bleeding from the underlying small capillaries of the choroid surface.
  • tissue paper e.g., tissue paper
  • a variety of procedures may be employed to improve the "receptivity" of the CAM which would favor rapid fusion of the choroid vessels with microvascular elements exposed at the surface of the implant.
  • Critical to survival of the implant is the rapid fusion of vessels which will provide the implant with blood from the circulatory system of the developing embryo. This fusion is executed within a matter of minutes by micro-vascular elements within the egg which identify the exposed micro-vascular elements of the implant. Little is known of the dynamics involved in this recognition process, but it is assumed to depend, in part, on the superficial location of the extra-embryonic coelomic vessels immediately below or with the choroid epithelial.
  • the abraded choroid epithelial cells may move away from points of contact with the implanted tissue and to thereby expose underlying vascular elements of the choroid.
  • Vascular fusion is sometimes also favored by covering the implant with a small (5 mm x 5 mm) sterile, transparent plastic "chip" (Gel-Bond, FMC Corp.) whose weight and hydrophyllic surface promote contact with the CAM while preventing drying of the implant.
  • the window of the egg is closed with tape and the edges are sealed by means of paraffin wax applied by means of a hot scalpel blade.
  • the eggs are then incubated at 37 degrees Celsius.
  • Implants may be inspected by placing the egg under the stereoscopic microscope, removing the tape window, and rotating it so the implant is visible. Photographs may also be taken at this and prior stages using the stereoscopic microscope. At high magnifi- cation it is possible to determine the viability of the implant by visualizing blood flow in small surface vessels which develop at the implant - CAM interface within one or two days after implantation. Such vessels continue to increase in size with time, and certain types of tissue (i.e., adrenal medullary tissues) can be distinguished by virtue of its high degree of vascularization.
  • tissue i.e., adrenal medullary tissues
  • Re-implantation of the conditioned implants into a mammalian host is effected by anesthetizing the recipient, and, using standard surgical procedures known to those skilled in the art, exposing a portion of the target organ provided with a non-traumatized micro-vascular bed.
  • stereotaxic procedures known to those skilled in the art, are employed by which the tissue can be delivered into the proper location with minimal trauma.
  • the implants are readied for reimplantation by first cooling them (while still in the egg) in a refrigerator for a few minutes.
  • the shell window is then opened and approximately 1 to 2 cubic centimeters of cold culture media is used to irrigate the implant surface. After 20 to 30 seconds the culture media is aspirated to expose the implant, and the underlying choroid membrane is carefully stripped away.
  • the implant is then removed from the remaining allantoic-mesenchyme surface by means of carefully controlled "aspiration" using a large gauge hypodermic needle whose tip has been modified to provide a sharpened, round, non- oblique aperture. Suction for such aspiration is provided by a tightly fitting "plunger” consisting of a second filled needle which can be withdrawn to create a vacuum. The aspirated tissues in the lumen of the larger (outer) needle shaft can then be safely conveyed to the reimplantation site in the mammalian host where it can be deposited either on the surface or within the prescribed tissue.
  • the implant is remove by a circumscribed incision followed by a trimming of surrounding tissue.
  • Example 1 In the Treatment of Alopecia Alopecia (hair-loss) can presently be treated by removing skin plugs from a hair-covered skin area of a balding subject and implanting them in the areas of baldness. This approach is limited because a balding subject has an ever-shrinking reservoir of appropriate hair-covered skin.
  • Dermal papillae contain cells capable of inducing hair growth, and unknown growth factors, arising from cells in dermal papillae, must be continuously provided to sustain hair growth. Baldness arises from a loss of hair due to a prolonged period of inactivity of the stem cells in the papillae of particular follicles which give rise to the cells required for hair growth and maintenance.
  • the approach disclosed herein involves elaborating stem cells derived from dermal papillae of active hair follicles on or in the CAM of a chicken egg. Growth of these stem cells on the CAM creates a reservoir of highly active autogenic stem cells and provide a substantial mass of tissue, that is transplantable to areas of baldness.
  • This autotransplanted tissue is implanted under inactive follicles and subsequently exerts a stimulatory effect on the endogenous stem cells of the dermal papillae, and on related keratinocytes, resulting in hair growth.
  • Example 2 In the Treatment of Human Infertility
  • the techniques commonly referred to as in vitro fertilization include the collection of oocytes from a donor (which may also be the recipient) the fertilization in vitro of at least one oocyte, and its subsequent reimplantation on or in the uterine epithelium of the recipient mother.
  • One of the most difficult hurdles in this procedure is the reimplantation step. Only one in six (or more) attempts results in a fetus that goes to term.
  • the fertilized egg is first allowed to implant into uterine epithelial implant tissue (taken from the recipient mother) which is in the process of growing on the CAM. After implantation and establishment of the embryo in this epithelial implant, the entire fertilization unit is then reimplanted into the mother. Briefly, a small explant of uterine epithelium is obtained either before or at the time of egg recovery and is grown "stroma-down" on the CAM.
  • the uterine epithelium can be prepared to receive the fertilized blastocyst by hormonal conditioning. After fertilization in vitro. the mammalian embryo is transferred to the surface of the uterine tissue explant and allowed to implant. The implantation can be certified by visual inspection. When growth and implantation is assured, the entire fertilization unit, including its highly vascular stroma would be microsurgically reimplanted back into the uterine wall of the mother.
  • the efficiency of embryo implantation is increased due to the ability to condition the epithelium without exposing the recipient to systemic hormonal treatment, an additional advantage results from the fact that the success of implantation can be ascertained prior to insertion of the embryo into the recipient, thereby avoiding unnecessary patient trauma.
  • the zygote (fertilized oocyte) is cultured in a small plastic enclosure within the extraembryonic coelom of the CAM rather than first culturing uterine epithelial tissue on the CAM and subsequently implanting the blastocyst into this cultured tissue.
  • the advantage of this approach is that it keeps the entire fertilization unit small ( ⁇ 3mm) which improves the ultimate in vivo reimplantation efficiency.
  • the oocyte is fertilized directly on the CAM rather than in a culture dish or test tube.
  • a 2mm hole covered with a 3mm gold screen is situated in a sterilized, transparent, hydrophyllic plastic chip (Gel Bond, FMC Corp.) about 3-7mm in diameter.
  • the choroid epithelium is then removed from a 2mm x 2mm site by gentle abrasion with a recently fine-polished glass rod without producing bleeding.
  • the plastic chip containing the gold-covered hole is then placed over the abrasion site on the CAM and the hole allowed to fill with the coelomic fluid (free of blood) . Then the oocyte together with its adherent cumulus (coronal) cells is placed in the hole.
  • oocyte While the oocyte matures it is treated with hyaluronidase which greatly reduces the number of coronal cells and exposes the oocyte surface. After the oocyte has matured, spermatozoa are then added and co-incubated with the oocyte so as to permit fertilization.
  • the advantage of this approach is that the embryonic environment of the CAM is more conducive to successful fertilization and subsequent survival of the fertilized zygote than is a test tube environment. This increases the overall efficiency of the in vitro fertilization procedure.
  • Example 5 In the Treatment of Parkinsonism
  • the method of culturing mammalian tissue on the avian CAM is used to condition tissue derived from autogenous adrenal medulla that is to be used for brain transplants to treat human subjects suffering from Parkinsonism.
  • the lack of survival of the implant at its point of insertion has emerged as the principal limitation to success of the procedure (See e.g. Ding, Y.J. et al. Chin Med J (1988) 101:631; Hansen, J.T. et al, Exp Neurol (1988) 102:65).
  • the surgical techniques of adrenal medullary explantation and striatum implantation is known to those skilled in the art (Id.) .
  • the tissue to be implanted in the striatum of a subject afflicted with Parkinsonism is derived from human fetal tissue. More specifically, dopamine producing neurons from the ventral mesencephalic region of abortus brain tissue is implanted onto the CAM of an avian embryo. 5 to 10 days later, the conditioned fetal tissue is excised from the CAM and implanted into the striatum of a human subject suffering from Parkinsonism. Stereotaxic techniques are used to assure proper placement. These techniques are well known to those skilled in the art. The patients are treated with a cyclosporine, azathioprine, and steroid regime to minimize the risk of graft rejection.
  • Example 7 In Somatic Cell Gene Therapy Using gene transfer technology known to those skilled in the art, a gene is inserted into autologous somatic cells of a patient suffering from a disease characterized by a deficiency of a naturally occurring gene product (e.g. diabetes and insulin) or a disease characterized by its ameliorative response to the introduction of a gene product (e.g. heart disease and tissue plasminogen activator) .
  • a gene product e.g. heart disease and tissue plasminogen activator
  • transduced epithelial keratinocytes are used to provide a "skin patch" from which the gene product is secreted; transduced endothelial cells are introduced into vascular grafts to provide direct secretion of a gene product into the circulatory system; and transduced parenchymal cells (such as hepatocytes) provide organ-specific introduction of a gene product.
  • genetically engineered (e.g. transformed or transduced) cells are first introduced onto the CAM of a developing avian embryo and cultured for 5-10 days, in the case of a chick egg, or 10-20 days in the case of an ostrich egg. During this culturing, the introduced cell population expands and forms a tissue which then becomes vascularized. This conditioned tissue is subsequently excised and homotypically reimplanted in the desired location within the patient using the techniques described supra. Autogenic cells which have been genetically engineered may also be used in combination with the other methods of treatment described supra. For instance, adrenal medulla cells can be genetically altered to up-regulate the production of dopamine, prior to their implantation on the CAM and subsequent reimplantation in the brain of Parkinson patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Immunology (AREA)
  • Animal Husbandry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Computer And Data Communications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Cette invention concerne un procédé de traitement d'un mammifère ayant besoin d'une implantation de tissu en utilisant un ÷uf amniotique en développement qui possède une membrane chorioallantoïque (CAM); en implantant des cellules ou des tissus mammifères sur la membrane chorioallantoïque de manière à produire un tissu mammifère conditionné; en enlevant le tissu conditionné de ladite membrane chorioallantoïque au moyen d'une excision; et en réimplantant le tissu conditionné dans le mammifère. L'invention concerne également des compositions utilisées à cet effet et des procédés de traitement.
EP19910908414 1990-04-17 1991-04-17 Methods of tissue implantation Withdrawn EP0528842A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51329090A 1990-04-17 1990-04-17
US513290 1990-04-17

Publications (2)

Publication Number Publication Date
EP0528842A1 EP0528842A1 (fr) 1993-03-03
EP0528842A4 true EP0528842A4 (en) 1993-06-30

Family

ID=24042643

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910908414 Withdrawn EP0528842A4 (en) 1990-04-17 1991-04-17 Methods of tissue implantation

Country Status (5)

Country Link
EP (1) EP0528842A4 (fr)
JP (1) JPH05509292A (fr)
AU (1) AU7746091A (fr)
CA (1) CA2080464A1 (fr)
WO (1) WO1991016419A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10005329A1 (de) * 2000-02-08 2001-09-20 Albert Scheller Humanisiertes, vitalisiertes Haarbewachsen und Haarwiederbewachsen mit subkutanen Kanüleneinstich-Haut-Färbungs-Zeichnungsverfahren
WO2001072120A2 (fr) * 2000-03-24 2001-10-04 Geron Corporation Technique de maintien de la gestation
CN100362972C (zh) * 2004-12-24 2008-01-23 李宇 人工毛乳头替代结构及其制作方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000201A1 (fr) * 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Cellules epitheliales exprimant un materiau genetique etranger
EP0236014A1 (fr) * 1986-02-21 1987-09-09 University of Dundee Stimulation de la chevelure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000201A1 (fr) * 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Cellules epitheliales exprimant un materiau genetique etranger
EP0236014A1 (fr) * 1986-02-21 1987-09-09 University of Dundee Stimulation de la chevelure

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EXPERIMENTAL CELL BIOLOGY vol. 57, no. 4, October 1989, BASEL, CH pages 219 - 227 K. SPANEL-BOROWSKI 'VASCULARIZATION OF OVARIES FROM GOLDEN HAMSTERS FOLLOWING IMPLANTATION INTO THE CHICK CHORIOALLANTOIC MEMBRANE.' *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 86, no. 22, November 1989, WASHINGTON US pages 9011 - 9014 J.A. WOLFF ET AL. 'GRAFTING FIBROBLASTS GENETICALLY MODIFIED TO PRODUCE L-DOPA IN A RAT MODEL OF PARKINSON DISEASE.' *
See also references of WO9116419A1 *

Also Published As

Publication number Publication date
AU7746091A (en) 1991-11-11
EP0528842A1 (fr) 1993-03-03
WO1991016419A1 (fr) 1991-10-31
CA2080464A1 (fr) 1991-10-18
JPH05509292A (ja) 1993-12-22

Similar Documents

Publication Publication Date Title
Borges et al. Chorioallantoic membrane angiogenesis model for tissue engineering: a new twist on a classic model
Billingham et al. Studies on the conservation of epidermal specificities of skin and certain mucosas in adult mammals
MORIYAMA et al. Progesterone facilitates implantation of xenogenic cultured cells in hamster uterus
CN101757691B (zh) 一种组织工程角膜的制备方法
CN100503814C (zh) 一种用于治疗皮肤缺损的可移植性产品的制备方法
Hsu Differentiation in vitro of mouse embryos to the stage of early somite
WO2008083223A1 (fr) Procédés pour la mise en culture de cellules dermiques pour le traitement de lésions cutanées telles que des brûlures
CN101102800A (zh) 使用羊膜的片状组合物及其制作方法
EP1702632B1 (fr) Procede de pousse de cheveux
US20200078492A1 (en) Process for obtaining a functional dermal substitute of decellurized amniotic membrane from the placenta combination with keratinocytes and its use as an agent for tissue regeneration of the skin
CN104087551A (zh) 一种体外分离培养人的表皮细胞的新方法
Boyce Methods for the Serum-Free Culture of Keratinocytes and Transplantation of Collagen—GAG-Based Skin Substitutes
Hsu Embryo growth and differentiation factors in embryonic sera of mammals
US20030202965A1 (en) Methods and compositions for the preparation of cell transplants
KR20120127468A (ko) 성장하는 사슴뿔에서 유래한 줄기세포로부터의 세포 균질현탁액, 이의 수득 방법 및 이의 용도
US6585969B1 (en) Non-viable keratinocyte cell composition or lysate for promoting wound healing
TWI389696B (zh) 人工腎臟前驅物及其製造方法
EP0528842A4 (en) Methods of tissue implantation
BRPI0708039A2 (pt) células alimentadoras derivadas de células-tronco de tecido
CN114134107B (zh) 一种间充质干细胞参与的人造卵巢及其制备方法和应用
JP5164439B2 (ja) 毛乳頭細胞培養方法
CN107338216A (zh) 人工表皮片、其制备方法与应用
CN112569227A (zh) 一种具有神经保护功能的3d立体移植材料体系及其应用
CN110199985A (zh) 一种神经元冻存液的制备方法
US20090148416A1 (en) Angiogenically induced transplants and methods for their use and manufacture

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19930511

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950124

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950607